Study guide

7.3 Endocrine Control of Calcium and Phosphate

Overseas Registration Examination ORE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: ORE Part 1 — Exam Blueprint, Logistics and Strategy

1.1 Structure and Format of ORE Part 1 1.2 The Official Blueprint and Preparing for Practice 1.3 Eligibility, Fees, Attempts and Time Limits

2 Chapter 2: Anatomy of the Head and Neck

2.1 The Trigeminal Nerve and Dental Innervation 2.2 The Facial Nerve and Parotid Region 2.3 The Temporomandibular Joint and Muscles of Mastication 2.4 The Infratemporal Fossa and Spread of Odontogenic Infection

3 Chapter 3: Dental Anatomy, Morphology and Occlusion

3.1 Permanent and Primary Tooth Morphology 3.2 Functional Occlusion: Centric Relation, Guidance and Interferences 3.3 Classifying Occlusion: Angle and BSI Incisor Relationships

4 Chapter 4: Genetics, Embryology and Odontogenesis

4.1 Stages of Odontogenesis and Molecular Signalling 4.2 Amelogenesis and Enamel Microstructure 4.3 Dentinogenesis and the Pulp-Dentine Complex 4.4 Cementum, the Periodontal Ligament and Oral Mucosa 4.5 Genetic and Developmental Dental Anomalies

5 Chapter 5: Oral Biology and Salivary Physiology

5.1 Salivary Gland Anatomy, Microarchitecture and Innervation 5.2 Salivary Secretion, Flow Rates and Autonomic Control 5.3 Salivary Buffering Systems and Protective Macromolecules 5.4 Physiology of Mastication and Deglutition 5.5 Taste, Lingual Papillae and Gustatory Pathways 5.6 Xerostomia, Sjogren's Syndrome and Salivary Diagnostics

6 Chapter 6: Physiology of the Major Body Systems

6.1 Cardiovascular and Respiratory Physiology 6.2 Renal, Endocrine and Gastrointestinal Physiology 6.3 Haematology and Haemostasis 6.4 Neurophysiology, Pain and the Autonomic Nervous System

7 Chapter 7: Bone Biology, Calcium Homeostasis and Healing

7.1 Microstructure and Architecture of Alveolar Bone 7.2 Bone Remodelling and the RANK/RANKL/OPG Axis 7.3 Endocrine Control of Calcium and Phosphate 7.4 Extraction Socket Healing and Ridge Resorption 7.5 Impaired Healing: MRONJ, Osteoradionecrosis and Systemic Risk

8 Chapter 8: Oral Microbiology and Biofilm Ecology

8.1 The Oral Microbiome and Biofilm Development 8.2 Cariogenic Microbiology: Mutans Streptococci and Lactobacilli 8.3 Ecological Hypotheses of Dental Caries 8.4 Biofilm Tolerance and the Case for Mechanical Plaque Control

9 Chapter 9: Immunology Relevant to Oral Disease

9.1 Innate Mucosal Immunity and Gingival Crevicular Fluid 9.2 Cellular Immunity in the Periodontium 9.3 Microbial Pathogenesis: Complexes and Keystone Pathogens 9.4 Host-Mediated Tissue Destruction 9.5 Hypersensitivity Reactions in Dental Practice 9.6 Autoimmune Mucocutaneous Bullous Disease 9.7 Immunodeficiency and Oral HIV Manifestations

10 Chapter 10: General Pathology and Neoplasia

10.1 Cellular Adaptation and Mechanisms of Cell Death 10.2 Inflammation, Wound Healing and Repair 10.3 Principles of Neoplasia and Carcinogenesis 10.4 TNM Staging of Oral Cavity Carcinoma

11 Chapter 11: Statistics and Research Methods

11.1 Study Designs and the Hierarchy of Evidence 11.2 Descriptive and Inferential Statistics 11.3 Diagnostic Test Performance 11.4 Critical Appraisal, Bias and Research Governance

12 Chapter 12: Human Disease: Cardiovascular and Respiratory

12.1 Infective Endocarditis and NICE CG64 12.2 Hypertension and Blood Pressure Thresholds for Dental Care 12.3 Angina, Myocardial Infarction and Antiplatelet Therapy 12.4 Asthma, COPD and Respiratory Emergencies

13 Chapter 13: Human Disease: Endocrine, Haematological and Renal

13.1 Diabetes Mellitus and the Periodontal Axis 13.2 Congenital Bleeding and Clotting Disorders 13.3 Anticoagulants and Antiplatelets: The SDCEP Protocol 13.4 Chronic Kidney Disease and Haemodialysis

14 Chapter 14: Human Disease: Gastrointestinal, Hepatic and Neurological

14.1 Gastrointestinal Disease and Intrinsic Dental Erosion 14.2 Liver Disease, Coagulopathy and Viral Hepatitis 14.3 Epilepsy, Stroke and Transient Ischaemic Attack 14.4 Trigeminal Neuralgia, Bell's Palsy and Giant Cell Arteritis

15 Chapter 15: Oral Aspects of Human Disease

15.1 Oral Manifestations of Systemic Disease 15.2 Orofacial Pain and Temporomandibular Disorders 15.3 Dry Mouth, Altered Taste and Halitosis

16 Chapter 16: Infection Prevention and Control

16.1 The Decontamination Cycle, Sterilization and Waterlines 16.2 Routes of Transmission and Blood-Borne Viruses

17 Chapter 17: Dental Materials

17.1 Dental Amalgam: Metallurgy and UK Regulation 17.2 Resin Composites: Chemistry and Placement 17.3 Dental Adhesive Systems 17.4 Acid Etching, the Hybrid Layer and MMP Degradation 17.5 Glass Ionomer Cements, RMGICs and Compomers 17.6 Impression Materials and Digital Scanning 17.7 Luting Cements and Adhesive Conditioning Protocols 17.8 Dental Ceramics and Cast Alloys 17.9 Gypsum Products, Waxes and Denture Base Polymers

18 Chapter 18: Behavioural Sciences Relevant to Oral Health Care

18.1 Health Behaviour Models and Behaviour Change 18.2 Dental Anxiety and Phobia 18.3 Psychosocial and Sociological Determinants of Oral Health

19 Chapter 19: Patient Assessment and Diagnosis

19.1 History Taking and Clinical Examination 19.2 Special Investigations and Reaching a Diagnosis

20 Chapter 20: Treatment Planning and Risk-Based Care

20.1 Treatment Planning and Sequencing 20.2 Risk Assessment, Recall Intervals and Preventive Planning

21 Chapter 21: Cariology and Caries Risk Assessment

21.1 Caries Pathogenesis and the Stephan Curve 21.2 Histopathology of Enamel and Dentinal Caries 21.3 Caries Diagnosis, ICDAS and Risk Assessment

22 Chapter 22: Operative Dentistry and Minimal Intervention

22.1 Minimal Intervention and Selective Caries Removal 22.2 Pulp Vitality Assessment and Biological Pulp Capping 22.3 Cavity Design, the C-Factor and Margin Geometry

23 Chapter 23: Endodontics

23.1 Pulp Histology and the Low-Compliance Environment 23.2 Pulpal Neurophysiology and Dentine Hypersensitivity 23.3 Pulpal and Periapical Diagnostic Terminology 23.4 Endodontic Diagnostic Testing 23.5 Access Cavity Design and Canal Configurations 23.6 Working Length Determination and Canal Preparation 23.7 Chemical Disinfection and Irrigant Activation 23.8 Medicaments, Obturation Materials and Techniques 23.9 Restoring Endodontically Treated Teeth 23.10 Endodontic Emergencies, Cracked Teeth and Root Fracture

24 Chapter 24: Periodontology

24.1 The 2018 Classification and Periodontal Health 24.2 Plaque-Induced and Non-Plaque-Induced Gingival Disease 24.3 Staging and Grading Periodontitis 24.4 Peri-Implant Disease and Systemic Risk Factors 24.5 The Basic Periodontal Examination 24.6 Simplified BPE in Children and Full Periodontal Charting 24.7 Furcation Involvement, Mobility and Occlusal Trauma 24.8 The BSP Stepwise Treatment Framework 24.9 Periodontal Instrumentation and Healing 24.10 Re-Evaluation, Endpoints and Periodontal Surgery 24.11 Crown Lengthening, Supracrestal Attachment and Supportive Care

25 Chapter 25: Fixed Prosthodontics

25.1 Biomechanical Principles of Tooth Preparation 25.2 Margin Design and the Supracrestal Attachment 25.3 Bridge Design and Resin-Bonded Bridges 25.4 Gingival Retraction, Provisionals and Temporary Cements

26 Chapter 26: Removable Prosthodontics

26.1 Removable Partial Dentures: Classification, Design and Surveying 26.2 Complete Dentures: Principles, Impressions and Jaw Registration

27 Chapter 27: Paediatric Dentistry

27.1 Primary Tooth Anatomy and Caries Management Strategies 27.2 Preformed Metal Crowns and the Hall Technique 27.3 Pulp Therapy in Primary Teeth 27.4 Extractions in the Primary Dentition 27.5 Non-Pharmacological Behaviour Management 27.6 Inhalation Sedation in Paediatric Dentistry 27.7 The Developing Dentition and Space Management 27.8 Serial Extraction and Non-Nutritive Sucking Habits

28 Chapter 28: Dental Traumatology

28.1 Trauma Assessment and Fractures of Permanent Teeth 28.2 Luxation Injuries, Avulsion and Replantation 28.3 Primary Tooth Trauma and Splinting Specifications

29 Chapter 29: Orthodontics

29.1 Extraoral Orthodontic Assessment 29.2 Intraoral Occlusal Assessment 29.3 Skeletal Pattern and Cephalometric Analysis 29.4 IOTN and NHS Treatment Eligibility 29.5 Upper Removable Appliances 29.6 Functional and Fixed Appliances 29.7 Biology of Orthodontic Tooth Movement 29.8 Orthodontic Risks and Retention

30 Chapter 30: Oral Surgery

30.1 Exodontia Biomechanics and Instrument Selection 30.2 Surgical Flap Design, Bone Removal and Suturing 30.3 Third Molar Surgery and NICE Guidance 30.4 Dry Socket and Oroantral Communication 30.5 Odontogenic Infection and Fascial Space Spread

31 Chapter 31: Oral Medicine

31.1 Recurrent Aphthous Stomatitis 31.2 Oral Candidiasis 31.3 Viral Oral Infections 31.4 Reactive Soft Tissue Lesions and the Epulides 31.5 Oral Potentially Malignant Disorders 31.6 Oral Squamous Cell Carcinoma, Urgent Referral and Biopsy

32 Chapter 32: Oral Pathology

32.1 Odontogenic and Non-Odontogenic Cysts 32.2 Odontogenic Tumours 32.3 Obstructive and Reactive Salivary Gland Disease 32.4 Salivary Gland Neoplasms

33 Chapter 33: Therapeutics and Prescribing

33.1 Local Anaesthetic Chemistry and Mechanism of Action 33.2 UK Local Anaesthetic Formulations 33.3 Vasoconstrictors, Maximum Doses and Systemic Toxicity 33.4 Analgesics for Acute Dental Pain 33.5 Antimicrobial Stewardship and First-Line Regimens 33.6 Antifungal and Antiviral Therapeutics

34 Chapter 34: Medical Emergencies in Dental Practice

34.1 The ABCDE Approach and the Emergency Drug Kit 34.2 Anaphylaxis and Acute Coronary Syndrome 34.3 Hypoglycaemia, Acute Asthma and Seizures 34.4 Syncope, Adrenal Crisis, Choking and Resuscitation

35 Chapter 35: Dental Radiology and Radiation Protection

35.1 Radiation Physics, Filtration and Collimation 35.2 Intraoral, Bitewing and Occlusal Projections 35.3 Dental Panoramic Tomography: Principles, Positioning and Errors 35.4 Lateral Cephalometry and Cone Beam CT 35.5 Systematic Reporting and Radiographic Caries Diagnosis 35.6 Radiology of Periodontal Bone Loss and Jaw Lesions 35.7 Radiographic Quality Assurance 35.8 IRR17 and IR(ME)R 2017

36 Chapter 36: Special Care Dentistry and Conscious Sedation

36.1 Special Care Dentistry, Risk Stratification and Sedation Principles 36.2 Inhalation Sedation with Nitrous Oxide 36.3 Intravenous Sedation with Midazolam 36.4 Oral Sedation and General Anaesthesia Referral

37 Chapter 37: Dental Public Health

37.1 Delivering Better Oral Health and the Fluoride Toolkit 37.2 Oral Health Epidemiology and Indices 37.3 Inequalities, Water Fluoridation and Population Prevention 37.4 NHS Dental Services, Access and Commissioning

38 Chapter 38: Communication and Interpersonal Skills

38.1 Patient Communication and Shared Decision-Making 38.2 Breaking Bad News, Complaints and the Duty of Candour 38.3 Referrals, Records and Communication with the Team

39 Chapter 39: Consent and Capacity

39.1 Valid Consent and the Montgomery Standard 39.2 The Mental Capacity Act 2005 39.3 Best Interests Decisions and Lasting Power of Attorney 39.4 Consent in Children and Young People 39.5 Safeguarding Children and Vulnerable Adults 39.6 Confidentiality, Data Protection and Lawful Disclosure

40 Chapter 40: Clinical Professionalism and the GDC

40.1 The General Dental Council and Standards Principles 1 to 4 40.2 GDC Standards: Principles 5 to 9 40.3 The GDC Fitness to Practise Process 40.4 Clinical Governance and the Audit Cycle

41 Chapter 41: Health and Safety Law in Dental Practice

41.1 Health and Safety Legislation, COSHH, RIDDOR and Sharps

42 Chapter 42: Self-Management and Professional Development

42.1 Enhanced CPD, Lifelong Learning and Reflective Practice 42.2 Managing Time, Stress and Clinical Wellbeing 42.3 Leadership, Delegation and Practice Management

7.3 Endocrine Control of Calcium and Phosphate

Key Takeaways Explain This Topic AI

Ionised calcium is normally 1.10 to 1.35 mmol/L, total serum calcium 2.20 to 2.60 mmol/L and phosphate 0.8 to 1.5 mmol/L.

Parathyroid hormone raises calcium and lowers phosphate by acting on osteoblast PTH1R receptors, renal reabsorption and renal 1-alpha-hydroxylase.

Calcitriol raises both calcium and phosphate by increasing intestinal absorption through TRPV6 and calbindin.

FGF-23 from osteocytes lowers phosphate by suppressing NaPi-IIa and NaPi-IIc cotransporters and renal 1-alpha-hydroxylase.

Vitamin D deficiency produces rickets in growing bone and osteomalacia in mature bone.

Last updated: September 2026

4. Endocrine Regulation of Systemic Calcium and Phosphate Homeostasis

Normal neuromuscular transmission, blood coagulation, enzyme activation, and skeletal structural integrity require tight regulation of extracellular ionized calcium ( [Ca²⁺]: 1.10–1.35 mmol/L ; total serum calcium: 2.20–2.60 mmol/L ) and inorganic phosphate ( 0.8–1.5 mmol/L ).

Parathyroid Hormone (PTH)

An 84-amino acid peptide synthesized by the chief cells of the parathyroid glands .

Released in response to minute decreases in extracellular ionized calcium detected by the G-protein coupled Calcium-Sensing Receptor (CaSR) on parathyroid cell membranes.

Actions:

Bone: Binds to PTH1R receptors on osteoblasts (osteoclasts lack PTH receptors). Osteoblasts respond by upregulating membrane-bound RANKL and downregulating OPG, stimulating osteoclast-mediated bone resorption to rapidly release calcium and phosphate into the circulation.

Kidney: Stimulates calcium reabsorption in the distal convoluted tubule. Simultaneously, it inhibits phosphate reabsorption in the proximal convoluted tubule by internalizing NaPi-IIa cotransporters , causing massive phosphaturia. This prevents calcium-phosphate precipitation (Ca × PO₄ solubility product). Concurrently, PTH upregulates renal 1α-hydroxylase (CYP27B1) .

Net Effect: Elevates serum calcium (Ca²⁺↑); decreases serum phosphate (PO₄³⁻↓) .

1,25-Dihydroxyvitamin D3 (Calcitriol)

A steroid hormone derived from skin 7-dehydrocholesterol following UVB photolysis, which undergoes 25-hydroxylation in the liver (CYP2R1) and subsequent 1α-hydroxylation in the renal proximal tubule (CYP27B1, stimulated by PTH and inhibited by FGF-23).

Actions:

Intestine: Calcitriol binds the nuclear Vitamin D Receptor (VDR) in enterocytes, transcribing apical calcium channels ( TRPV6 ), cytoplasmic calcium shuttle proteins ( Calbindin-D9k ), and basolateral extrusion pumps ( PMCA1b ). This dramatically increases active transcellular intestinal absorption of dietary calcium and phosphate.

Bone: Synergizes with PTH to support osteoclastogenesis during hypocalcaemia, but is fundamentally essential for normal osteoblast function and mineralization of newly deposited osteoid. Severe deficiency causes rickets in children and osteomalacia in adults (failure of osteoid mineralization).

Net Effect: Elevates both serum calcium (Ca²⁺↑) and serum phosphate (PO₄³⁻↑) .

Calcitonin

A 32-amino acid peptide synthesized by the parafollicular C-cells of the thyroid gland .

Secreted in response to hypercalcaemia .

Actions: Binds directly to calcitonin receptors expressed on mature osteoclasts , immediately halting motility, retracting the ruffled border, and detaching the sealing zone, rapidly arresting bone resorption.

Net Effect: Decreases serum calcium (Ca²⁺↓) and phosphate (PO₄³⁻↓) . In adult humans, calcitonin plays only a weak, secondary regulatory role compared to PTH and calcitriol.

Fibroblast Growth Factor 23 (FGF-23) — The Phosphatonin Axis

A 251-amino acid endocrine peptide synthesized predominantly by osteocytes in response to elevated serum phosphate and elevated calcitriol.

Actions: Acts on the renal proximal tubule, requiring the obligate transmembrane co-receptor α-Klotho .

Downregulates NaPi-IIa and NaPi-IIc cotransporters , inducing profound renal phosphate excretion (phosphaturia).

Directly suppresses renal 1α-hydroxylase (CYP27B1) and upregulates the catabolic 24-hydroxylase (CYP24A1) , shutting down active calcitriol production to limit further intestinal phosphate absorption.

Net Effect: Decreases serum phosphate (PO₄³⁻↓) , preventing hyperphosphataemia and protecting against fatal vascular and ectopic soft-tissue calcification.

Hormone Principal Cellular Source Primary Secretory Trigger Target Organs Primary Biological Action Net Effect on Serum Minerals

PTH Parathyroid chief cells Hypocalcaemia (low ionized Ca²⁺) Bone, Kidney Resorbs bone, reabsorbs renal Ca²⁺, blocks renal PO₄³⁻, activates calcitriol Ca²⁺↑, PO₄³⁻↓

Calcitriol [1,25(OH)₂D₃] Renal proximal tubule (CYP27B1) Elevated PTH, hypophosphataemia Intestine, Bone Enhances active intestinal Ca²⁺ and PO₄³⁻ absorption Ca²⁺↑, PO₄³⁻↑

Calcitonin Thyroid parafollicular C-cells Hypercalcaemia Bone osteoclasts Inhibits osteoclastic ruffled border motility and resorption Ca²⁺↓, PO₄³⁻↓

FGF-23 Mature bone osteocytes Hyperphosphataemia, elevated calcitriol Kidney (with α-Klotho) Induces renal phosphate excretion, suppresses CYP27B1 PO₄³⁻↓, Calcitriol ↓

Why Dentists Are Asked About Calcium Metabolism

The blueprint places calcium and phosphate homeostasis in Paper A because the dentition and jaws are among the first places systemic mineral disturbance becomes visible. Hyperparathyroidism — primary from a parathyroid adenoma, or secondary to chronic kidney disease — raises parathyroid hormone, increases osteoclastic resorption and produces the classic radiographic triad of generalised loss of lamina dura, a ground-glass trabecular pattern and, in advanced disease, well-defined radiolucent brown tumours that are histologically identical to central giant cell granuloma. The examinable point is that a giant cell lesion in the jaws obliges the clinician to exclude hyperparathyroidism by measuring serum calcium, phosphate and parathyroid hormone before treating the lesion as a local problem.

Hypoparathyroidism , most often iatrogenic after thyroid surgery, produces hypocalcaemia with paraesthesia, carpopedal spasm, Chvostek's and Trousseau's signs, and in children enamel hypoplasia and delayed eruption. Rickets and osteomalacia from vitamin D deficiency produce large pulp chambers with pulp horns extending to the amelodentinal junction, hypoplastic enamel and increased risk of spontaneous pulpal infection.

Drugs Acting on Bone Turnover

The therapeutic manipulation of this axis is directly examinable. Bisphosphonates bind hydroxyapatite and are internalised by osteoclasts, inhibiting the mevalonate pathway and inducing osteoclast apoptosis; they have a very long skeletal half-life, so risk persists long after the drug is stopped. Denosumab is a monoclonal antibody against RANKL that prevents osteoclast differentiation; its effect reverses within months of discontinuation because it is not incorporated into bone. Romosozumab inhibits sclerostin and is both anabolic and antiresorptive. All three are associated with medication-related osteonecrosis of the jaw, and the distinction in skeletal persistence between bisphosphonates and denosumab is exactly the kind of discriminating fact an SBA distractor set is built around.